PH12021550539A1 - Purified capsular polysaccharides of streptococcus pneumoniae - Google Patents
Purified capsular polysaccharides of streptococcus pneumoniaeInfo
- Publication number
- PH12021550539A1 PH12021550539A1 PH12021550539A PH12021550539A PH12021550539A1 PH 12021550539 A1 PH12021550539 A1 PH 12021550539A1 PH 12021550539 A PH12021550539 A PH 12021550539A PH 12021550539 A PH12021550539 A PH 12021550539A PH 12021550539 A1 PH12021550539 A1 PH 12021550539A1
- Authority
- PH
- Philippines
- Prior art keywords
- streptococcus pneumoniae
- capsular polysaccharides
- purified capsular
- purified
- relates
- Prior art date
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract 3
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841031653 | 2018-09-23 | ||
| IN201841031654 | 2018-09-23 | ||
| PCT/IB2019/058036 WO2020058963A1 (en) | 2018-09-23 | 2019-09-23 | Purified capsular polysaccharides of streptococcus pneumoniae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550539A1 true PH12021550539A1 (en) | 2022-02-21 |
Family
ID=69886702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550539A PH12021550539A1 (en) | 2018-09-23 | 2021-03-11 | Purified capsular polysaccharides of streptococcus pneumoniae |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12048739B2 (enExample) |
| EP (1) | EP3852795A4 (enExample) |
| JP (2) | JP2022513562A (enExample) |
| KR (1) | KR102879391B1 (enExample) |
| CN (1) | CN113164581A (enExample) |
| AU (1) | AU2019341723C1 (enExample) |
| BR (1) | BR112021005425A2 (enExample) |
| MX (1) | MX2021003358A (enExample) |
| MY (1) | MY206212A (enExample) |
| PH (1) | PH12021550539A1 (enExample) |
| WO (1) | WO2020058963A1 (enExample) |
| ZA (1) | ZA202101663B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| ES3058336T3 (es) | 2017-12-06 | 2026-03-10 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos |
| CR20210333A (es) | 2018-12-19 | 2021-08-18 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso |
| KR20220017996A (ko) * | 2019-06-05 | 2022-02-14 | 머크 샤프 앤드 돔 코포레이션 | 면역원성 혈청형 35b 폐렴구균 폴리사카라이드-단백질 접합체 및 그를 제조하기 위한 접합 방법 |
| MY207887A (en) * | 2020-05-01 | 2025-03-26 | Sinocelltech Ltd | Method for improving immunogenicity of protein/peptide antigen |
| WO2022084852A1 (en) * | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| CA3200602A1 (en) * | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| EP4288106A4 (en) * | 2021-02-04 | 2025-06-04 | Merck Sharp & Dohme LLC | Lipid DNANOparticle adjuvant composition for pneumococcal conjugate vaccines |
| WO2024062494A1 (en) * | 2022-09-19 | 2024-03-28 | Biological E Limited | Method for the purification of capsular polysaccharides |
| CN117512031B (zh) * | 2023-10-16 | 2024-06-25 | 江苏金迪克生物技术股份有限公司 | 一种肺炎球菌荚膜多糖的纯化方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| ES2204900T3 (es) | 1992-02-11 | 2004-05-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Estructura inmuinogena de doble vector. |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| WO1995008348A1 (en) | 1993-09-22 | 1995-03-30 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| NZ304715A (en) | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| JP6502262B2 (ja) * | 2012-12-20 | 2019-04-17 | ファイザー・インク | 糖複合化方法 |
| PL3096786T3 (pl) * | 2014-01-21 | 2021-11-08 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
| CN110859957B (zh) | 2014-01-21 | 2024-04-12 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| CA2968491C (en) | 2014-11-20 | 2023-09-26 | Biological E Limited | Codon optimized polynucleotide for high level expression of crm197 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| EP3374376B1 (en) | 2015-11-09 | 2020-03-18 | Biological E Limited | Industrially scalable process for recovering biologically active recombinant carrier proteins |
| EP3436061A4 (en) * | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
| NZ752348A (en) * | 2016-09-30 | 2022-11-25 | Biological E Ltd | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| CN110366428B (zh) * | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| JP7680185B2 (ja) * | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| SMT202200356T1 (it) | 2017-04-22 | 2022-11-18 | Biological E Ltd | Un metodo migliorato per produzione ad alto livello di crm |
| WO2019050814A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| MX394767B (es) | 2017-09-07 | 2025-03-24 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
| CN111093650B (zh) | 2017-09-07 | 2024-03-01 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
-
2019
- 2019-09-23 MX MX2021003358A patent/MX2021003358A/es unknown
- 2019-09-23 KR KR1020217011738A patent/KR102879391B1/ko active Active
- 2019-09-23 WO PCT/IB2019/058036 patent/WO2020058963A1/en not_active Ceased
- 2019-09-23 BR BR112021005425-1A patent/BR112021005425A2/pt unknown
- 2019-09-23 MY MYPI2021001583A patent/MY206212A/en unknown
- 2019-09-23 CN CN201980076246.8A patent/CN113164581A/zh active Pending
- 2019-09-23 US US17/278,181 patent/US12048739B2/en active Active
- 2019-09-23 AU AU2019341723A patent/AU2019341723C1/en active Active
- 2019-09-23 EP EP19861817.5A patent/EP3852795A4/en not_active Withdrawn
- 2019-09-23 JP JP2021516582A patent/JP2022513562A/ja not_active Withdrawn
-
2021
- 2021-03-11 ZA ZA2021/01663A patent/ZA202101663B/en unknown
- 2021-03-11 PH PH12021550539A patent/PH12021550539A1/en unknown
-
2024
- 2024-06-12 US US18/741,232 patent/US12465632B2/en active Active
- 2024-08-07 JP JP2024130732A patent/JP2024160305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020058963A1 (en) | 2020-03-26 |
| KR20210062669A (ko) | 2021-05-31 |
| BR112021005425A2 (pt) | 2021-06-15 |
| AU2019341723B2 (en) | 2024-03-21 |
| US20240325516A1 (en) | 2024-10-03 |
| EP3852795A4 (en) | 2022-11-23 |
| ZA202101663B (en) | 2024-08-28 |
| CN113164581A (zh) | 2021-07-23 |
| US20210346488A1 (en) | 2021-11-11 |
| MX2021003358A (es) | 2021-05-27 |
| KR102879391B1 (ko) | 2025-10-30 |
| US12465632B2 (en) | 2025-11-11 |
| JP2022513562A (ja) | 2022-02-09 |
| AU2019341723A1 (en) | 2021-05-20 |
| JP2024160305A (ja) | 2024-11-13 |
| US12048739B2 (en) | 2024-07-30 |
| MY206212A (en) | 2024-12-04 |
| AU2019341723C1 (en) | 2026-01-22 |
| EP3852795A1 (en) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550539A1 (en) | Purified capsular polysaccharides of streptococcus pneumoniae | |
| MY191508A (en) | Production of beta-lactoglobulin preparations | |
| MX2017014891A (es) | Producto de queso con almidones modificados. | |
| WO2018081502A8 (en) | Synthetic bacteriophages and bacteriophage compositions | |
| PH12016501729B1 (en) | Glycosyl hesperetin and process for producing the same and uses thereof | |
| MX2019005535A (es) | Streptococcus thermophilus para uso en la preparación de productos fermentados. | |
| SA520411726B1 (ar) | مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه | |
| PH12019500264A1 (en) | Lactobacillus salivarius cjls1511, animal feed additive composition comprising same bacterium or dead cells thereof, and method for producing same dead cells | |
| MY192792A (en) | A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof | |
| PH12015502831B1 (en) | Process for producing dark brown natural cocoa | |
| WO2020123330A3 (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| MX2021004467A (es) | Productos lacteos filtrados acidos reducidos en carbohidratos. | |
| WO2018004224A3 (ko) | 신규 스포리치아과 미생물 및 그의 용도 | |
| MX2019010519A (es) | Metodo de sintesis de cristales de zeolita con agente de siembra. | |
| MY200521A (en) | Raw material for producing a refractory product, use of said raw material, and a refractory product comprising such a raw material | |
| MX2019007978A (es) | Mezcla para la fabricacion de un producto ceramico refractario no moldeado, procedimiento para la fabricacion de un producto ceramico refractario no moldeado asi como un producto ceramico refractario no moldeado fabricado por ello. | |
| ZA202100231B (en) | Non-viable bifidobacterium bifidum bacteria and uses thereof | |
| MX2020013380A (es) | Producto refractario, una mezcla para la fabricacion del producto, un procedimiento para la fabricacion del producto asi como un uso del producto. | |
| MX2020007246A (es) | Diseño de vacuna integral para el avance de enfermedad comensal. | |
| EA202190824A1 (ru) | Очищенные капсульные полисахариды streptococcus pneumoniae | |
| PL409330A1 (pl) | Szczepy Staphylococcus aureus do produkcji monoklonalnych preparatów fagowych pozbawionych zanieczyszczeń plazmidowym DNA | |
| MX2019001167A (es) | Derivados sinteticos estables de poliribosilribitolfosfato resistentes a la hidrolisis como vacunas contra haemophilus influenzae tipo b. | |
| MX2020007906A (es) | Composicion que comprende nuevas cepas de lactobacillus salivarius y metodo para la prevencion y el tratamiento de otitis e infecciones respiratorias de vias altas. | |
| WO2020013772A3 (en) | Method for producing a condensed dairy product | |
| PL413208A1 (pl) | Sposób wytwarzania 17α-metyloandrost-1,4-dien-3-on-17-olu |